MDS Nordion to start FDA-approved trial of TheraSphere in liver cancer

By Lisa Kerner

Charlotte, N.C., Sept. 26 - The Food and Drug Administration approved MDS Nordion's plans for the first clinical trial of its liver cancer treatment, TheraSphere.

MDS said it will enroll up to 150 patients with secondary liver cancer from five existing TheraSphere treatment centers in the United States.

During the TheraSphere treatment, tiny radioactive glass beads attack cancerous tumors in the liver, with minimal impact on healthy tissues and with fewer side effects than chemotherapy.

"This clinical trial will evaluate the effectiveness and safety of TheraSphere with the goal of making this cancer therapy more widely available to help more patients," president Steve West said in a news release.

MDS, based in Ottawa, specializes in radioisotopes, radiation and related technologies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.